PENTIFYLLINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H20N4O2
Molecular Weight	264.3235
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

InChI

InChIKey=MRWQRJMESRRJJB-UHFFFAOYSA-N

InChI=1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3

HIDE SMILES / InChI

Description
Sources: http://home.intekom.com/pharm/hmr/cosaldrt.html | https://www.ncbi.nlm.nih.gov/pubmed/170944 | https://www.ncbi.nlm.nih.gov/pubmed/227424

Pentifylline is an active vasodilating substance which does not affect blood sugar levels. Pentifylline inhibits the soluble and the particulate cyclic AMP phosphodiesterases from bovine platelets and rat brain ATPase. The inhibition of ATPase by pentifylline was not influenced by the change in Na /K ratio. Pentifylline in combination with Nicotinic acid indicated for the treatment of Cerebral circulatory disorders and Circulatory disorders of the eye. Pentifylline is well tolerated but it is recommended that blood pressure be monitored and if there is a severe drop in blood pressure, a drip infusion of plasma expander be administered. Coagulation states should also be closely watched.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 1 12 Target ID: CHEMBL2097166 Sources: https://www.ncbi.nlm.nih.gov/pubmed/170944	Inhibitor 8504	2.0 mM [IC50]
Phosphodiesterase 2A 7 Target ID: CHEMBL3477 Sources: https://www.ncbi.nlm.nih.gov/pubmed/170944	Inhibitor 8504	0.81 mM [IC50]
Brain ATPase (rat) 1 Target ID: Brain ATPase (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/227424	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cerebral circulatory disorders 1 Sources: http://home.intekom.com/pharm/hmr/cosaldrt.html	Primary		Approved 8583	COSALDON Approved Use Indicated for the treatment of brain performance disorders in old age, degenerative vascular diseases in the eye.
Circulatory disorders of the eye 1 Sources: http://home.intekom.com/pharm/hmr/cosaldrt.html	Primary		Approved 8583	COSALDON Approved Use Indicated for the treatment of brain performance disorders in old age, degenerative vascular diseases in the eye.

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70569#section=BioAssay-Results Page: 4.0	inconclusive [IC50 34.6713 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70569#section=BioAssay-Results Page: 52.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70569#section=BioAssay-Results Page: 52.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70569#section=BioAssay-Results Page: 3.0	yes [IC50 15.4871 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70569#section=BioAssay-Results Page: 4.0	yes [IC50 30.9008 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70569#section=BioAssay-Results Page: 57.0

PubMed

Title	Date	PubMed
A REPORT ON THE USE OF COSALDON IN GENERAL PRACTICE.	1963-12	14084642
[Pharmacology of 1-hexyl-3, 7-dimethylxanthine (SK-7)].	1962-03	13923515
[Treatment of cerebral arteriosclerosis with cosaldon].	1960-05-06	13833290
[Some aspects of the pharmacological activity of a new theophylline: 1-hexyl-3, 7-dimethylxanthine (SK-7)].	1960-01-01	13813225
[On the applicability of cosaldon in the treatment of cerebral sclerotic parkinsonism].	1959-08-07	13819571
[Cerebral sclerosis and its treatment with cosaldon].	1957-06-14	13451071

Patents

Sample Use Guides

In Vivo Use Guide

Cerebral and peripheral circulatory disorders: 400 mg one tablet twice daily (Initial and normal dose) or 400 mg tablet daily for as long as necessary (Maintenance dose). Circulatory disorders of the eye: 400 mg two or three times daily (Initial and normal dose) or 400 mg once or twice daily for as long as necessary (Maintenance dose).

Route of Administration: Oral

In Vitro Use Guide

The secretion of type-I collagen COOH-terminal peptide (PIP) into the culture medium in the presence of pentifylline (PTF) was significantly lower than that in the presence of pentoxifylline (PTX) at concentrations of 10-1000 ug/ml; its level in cell lysate in the presence of PTX at concentrations of 10-100 ug/ml.

Name

Type

Language

PENTIFYLLINE [MART.]

Preferred Name

English

PENTIFYLLINE

Official Name

English

1-HEXYLTHEOBROMINE

Systematic Name

English

pentifylline [INN]

Common Name

English

PENTIFYLLINE [MI]

Common Name

English

Pentifylline [WHO-DD]

Common Name

English

1-HEXYL-3,7-DIMETHYLXANTHINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327